collection
MENU ▼
Read by QxMD icon Read
search

Head and Neck cancer

shared collection
755 papers 100 to 500 followers
By Massimo Ghiani Medical Doctor involved in Head and neck cancer
https://read.qxmd.com/read/21865152/phase-ii-study-of-the-combination-of-cetuximab-and-weekly-paclitaxel-in-the-first-line-treatment-of-patients-with-recurrent-and-or-metastatic-squamous-cell-carcinoma-of-head-and-neck
#1
R Hitt, A Irigoyen, H Cortes-Funes, J J Grau, J A García-Sáenz, J J Cruz-Hernandez
BACKGROUND: The efficacy and safety of a novel combination of weekly paclitaxel and the epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab for the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck were investigated. PATIENTS AND METHODS: Patients received paclitaxel (80 mg/m(2)) and cetuximab (400/250 mg/m(2)), weekly, until disease progression or unacceptable toxicity. The primary end point was response rate...
April 2012: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/30821023/importance-of-the-immune-system-in-head-and-neck-cancer
#2
REVIEW
Adal H Mirza, Gareth Thomas, Christian H Ottensmeier, Emma V King
Head and neck squamous cell carcinoma (HNSCC) are a heterogeneous group of tumors, mainly caused by exposure to cigarette smoke and/or alcohol. In recent years, a virally driven subset of cancers driven by human papillomavirus subtype 16 [HPV-16]) has emerged. Our own data and data from other groups have demonstrated the favorable clinical outcome of HPV-driven oropharyngeal tumors and in both HPV+ and HPV- cancers the importance of a high density of tumor-associated lymphocytes for survival. These data underpin manipulation and activation of the patients' immune system by treatment, and as a result immunotherapy is rapidly taking its place in the management of HNSCC...
February 28, 2019: Head & Neck
https://read.qxmd.com/read/30835900/concurrent-chemoradiotherapy-with-weekly-versus-triweekly-cisplatin-in-locally-advanced-squamous-cell-carcinoma-of-the-head-and-neck-a-comparative-analysis
#3
REVIEW
Amr Mohamed, Brandon Twardy, Magdi A Zordok, Khuram Ashraf, Ayman Alkhoder, Kelly Schrapp, Conor Steuer, Zhengjia Chen, Suchita Pakkala, Rathi Pillai, J Trad Wadsworth, Kristin Higgins, Jonathan J Beitler, Suresh S Ramalingam, Taofeek K Owonikoko, Fadlo R Khuri, Dong M Shin, Madhusmita Behera, Nabil F Saba
BACKGROUND: Cisplatin-based chemoradiotherapy is standard of care for locally advanced squamous cell carcinoma of the head and neck. This systemic review compared efficacy and safety of weekly vs triweekly cisplatin in locally advanced squamous cell carcinoma of the head and neck. METHODS: Among 1500 prospective studies published from 1970 to 2015, 39 (18 weekly, 21 triweekly) including 3668 patients qualified for inclusion. Clinical outcomes were analyzed using weighted estimates and 2-tailed t test for comparisons; significance level was 0...
March 5, 2019: Head & Neck
https://read.qxmd.com/read/30856297/weekly-cisplatin-chemotherapy-dosing-versus-triweekly-chemotherapy-with-concurrent-radiation-for-head-and-neck-squamous-cell-carcinoma
#4
Ryan T Morse, Rohit G Ganju, Mindi J TenNapel, Prakash Neupane, Kiran Kakarala, Yelizaveta Shnayder, Allen M Chen, Christopher E Lominska
BACKGROUND: Triweekly high-dose cisplatin (100 mg/m2 ) with concurrent radiation therapy is the current standard of care in the definitive or appropriate postoperative setting in head and neck squamous cell carcinoma (HNSCC). We compared triweekly 100 mg/m2 with alternative weekly 40 mg/m2 and weekly <40 mg/m2 cisplatin regimens. METHODS: From 2011 to 2016, 163 patients received concurrent cisplatin and intensity-modulated radiotherapy for locally advanced HNSCC...
March 11, 2019: Head & Neck
https://read.qxmd.com/read/28602354/head-and-neck-cancer-pain
#5
REVIEW
Jakun W Ing
Pain is a significant morbidity resulting from head and neck cancer. Pain may also be the result of the treatments directed against head and neck cancer. An experienced practitioner may manage this pain by understanding the multifactorial mechanisms of pain and the various pharmacotherapies available. Pain should be managed with multiple medications in a multimodal approach, and nonpharmacologic therapies should be considered as well.
August 2017: Otolaryngologic Clinics of North America
https://read.qxmd.com/read/27010487/the-effects-of-swallowing-disorders-dysgeusia-oral-mucositis-and-xerostomia-on-nutritional-status-oral-intake-and-weight-loss-in-head-and-neck-cancer-patients-a-systematic-review
#6
REVIEW
Valentina Bressan, Simone Stevanin, Monica Bianchi, Giuseppe Aleo, Annamaria Bagnasco, Loredana Sasso
BACKGROUND: Combined-modality treatment of head and neck cancer is becoming more common, driven by the idea that organ(s) preservation should maintain patient appearance and the function of organ(s) involved. Even if treatments have improved, they can still be associated with acute and late adverse effects. The aim of this systematic review was to retrieve current data on how swallowing disorders, dysgeusia, oral mucositis, and xerostomia affect nutritional status, oral intake and weight loss in head and neck cancer (HNC) patients...
April 2016: Cancer Treatment Reviews
https://read.qxmd.com/read/29079897/the-case-volume-issue-in-head-and-neck-oncology
#7
REVIEW
Salvatore Alfieri, Ester Orlandi, Paolo Bossi
In the past few years, several evidences reported better outcomes, in terms of reduced toxicities and longer survival, for head and neck cancer (HNC) patients when "regionalized," namely if they are managed at "high-volume" cancer referral centers (CRC). The benefit of case volume has been demonstrated in HNC patients primarily treated with surgery and in those receiving curative radiotherapy and chemotherapy. Many factors could explain these positive results: organization, facilities, processes of care, quality assurance programs, professional expertise, technology, and patient referral bias...
October 27, 2017: Current Treatment Options in Oncology
https://read.qxmd.com/read/29082496/high-content-imaging-assays-for-il-6-induced-stat3-pathway-activation-in-head-and-neck-cancer-cell-lines
#8
Paul A Johnston, Malabika Sen, Yun Hua, Daniel P Camarco, Tong Ying Shun, John S Lazo, Jennifer R Grandis
In the canonical STAT3 signaling pathway, IL-6 receptor engagement leads to the recruitment of latent STAT3 to the activated IL-6 complex and the associated Janus kinase (JAK) phosphorylates STAT3 at Y705. pSTAT3-Y705 dimers traffic into the nucleus and bind to specific DNA response elements in the promoters of target genes to regulate their transcription. However, IL-6 receptor activation induces the phosphorylation of both the Y705 and S727 residues of STAT3, and S727 phosphorylation is required to achieve maximal STAT3 transcriptional activity...
2018: Methods in Molecular Biology
https://read.qxmd.com/read/29094074/progressive-resistance-training-in-head-and-neck-cancer-patients-undergoing-concomitant-chemoradiotherapy
#9
Camilla K Lonkvist, Anders Vinther, Bo Zerahn, Eva Rosenbom, Atul S Deshmukh, Pernille Hojman, Julie Gehl
Objectives: Patients with head and neck squamous cell carcinoma undergoing concomitant chemoradiotherapy (CCRT) frequently experience weight loss, especially loss of lean body mass (LBM), and reduced functional performance. This study investigated whether a 12-week hospital-based progressive resistance training (PRT) program during CCRT is feasible in the clinical setting before planning initiation of a larger randomized study which is the long-term goal. Study design: Prospective pilot study...
October 2017: Laryngoscope Investigative Otolaryngology
https://read.qxmd.com/read/29094075/genomics-and-advances-towards-precision-medicine-for-head-and-neck-squamous-cell-carcinoma
#10
REVIEW
Carter Van Waes, Omar Musbahi
Objective: To provide a review of emerging knowledge from genomics and related basic science, preclinical, and clinical precision medicine studies in head and neck squamous cell carcinoma (HNSCC). Data Sources: The Cancer Genome Atlas Network (TCGA) publications, PubMed-based literature review, and ClinicalTrials.gov. Review Methods: TCGA publications, PubMed, and ClinicalTrials.gov were queried for genomics and related basic science, preclinical, and developmental clinical precision medicine studies in HNSCC...
October 2017: Laryngoscope Investigative Otolaryngology
https://read.qxmd.com/read/29069302/mechanistic-overview-of-immune-checkpoints-to-support-the-rational-design-of-their-combinations-in-cancer-immunotherapy
#11
A Rotte, J Y Jin, V Lemaire
Checkpoint receptor blockers, known to act by blocking the pathways that inhibit immune cell activation and stimulate immune responses against tumor cells, have been immensely successful in the treatment of cancer. Among several checkpoint receptors of immune cells, cytotoxic T-lymphocyte-associated protein-4 (CTLA-4), programmed cell death protein-1 (PD-1), T-cell immunoglobulin and ITIM domain (TIGIT), T-cell immunoglobulin-3 (TIM-3) and lymphocyte activation gene 3 (LAG-3) are the most commonly targeted checkpoints for cancer immunotherapy...
January 1, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/27238227/head-and-neck-cancer-immunology-and-immunotherapeutics-basic-concepts-to-clinical-translational-approaches
#12
EDITORIAL
Ravindra Uppaluri, R Bryan Bell, John B Sunwoo
No abstract text is available yet for this article.
July 2016: Oral Oncology
https://read.qxmd.com/read/26351330/immunology-and-immunotherapy-of-head-and-neck-cancer
#13
REVIEW
Robert L Ferris
The immune system plays a key role in the development, establishment, and progression of head and neck squamous cell carcinoma (HNSCC). A greater understanding of the dysregulation and evasion of the immune system in the evolution and progression of HNSCC provides the basis for improved therapies and outcomes for patients. HNSCC cells evade the host immune system through manipulation of their own immunogenicity, production of immunosuppressive mediators, and promotion of immunomodulatory cell types. Through the tumor's influence on the microenvironment, the immune system can be exploited to promote metastasis, angiogenesis, and growth...
October 10, 2015: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/28619685/molecular-mechanisms-of-human-papillomavirus-related-carcinogenesis-in-head-and-neck-cancer
#14
REVIEW
Farhoud Faraji, Munfarid Zaidi, Carole Fakhry, Daria A Gaykalova
This review examines the general cellular and molecular underpinnings of human papillomavirus (HPV)-related carcinogenesis in the context of head and neck squamous cell carcinoma (HNSCC) and focuses on HPV-positive oropharyngeal squamous cell carcinoma in areas for which specific data is available. It covers the major pathways dysregulated in HPV-positive HNSCC and the genome-wide changes associated with this disease.
September 2017: Microbes and Infection
https://read.qxmd.com/read/28622889/turning-the-tide-clinical-utility-of-pd-l1-expression-in-squamous-cell-carcinoma-of-the-head-and-neck
#15
REVIEW
Astrid De Meulenaere, Tijl Vermassen, Sandrine Aspeslagh, Wouter Huvenne, Jo Van Dorpe, Liesbeth Ferdinande, Sylvie Rottey
The use of cytotoxic and/or targeted agents is the gold standard in first- and second-line treatment of metastatic head and neck cancer. Currently the focus of oncologic research is shifting to the implementation of immune checkpoint inhibitor regimens. Many trials are being performed evaluating the survival benefit of various PD-1/PD-L1 blocking antibodies in both solid and haematological malignancies. Also, evaluation of the predictive value of PD-L1 expression on tumour cells and immune cells is being explored...
July 2017: Oral Oncology
https://read.qxmd.com/read/24958820/human-papillomavirus-and-overall-survival-after-progression-of-oropharyngeal-squamous-cell-carcinoma
#16
RANDOMIZED CONTROLLED TRIAL
Carole Fakhry, Qiang Zhang, Phuc Felix Nguyen-Tan, David Rosenthal, Adel El-Naggar, Adam S Garden, Denis Soulieres, Andy Trotti, Vilija Avizonis, John Andrew Ridge, Jonathan Harris, Quynh-Thu Le, Maura Gillison
PURPOSE: Risk of cancer progression is reduced for patients with human papillomavirus (HPV) -positive oropharynx cancer (OPC) relative to HPV-negative OPC, but it is unknown whether risk of death after progression is similarly reduced. PATIENTS AND METHODS: Patients with stage III-IV OPC enrolled onto Radiation Therapy Oncology Group trials 0129 or RTOG 0522 who had known tumor p16 status plus local, regional, and/or distant progression after receiving platinum-based chemoradiotherapy were eligible for a retrospective analysis of the association between tumor p16 status and overall survival (OS) after disease progression...
October 20, 2014: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/24659647/clinical-benefit-of-cetuximab-and-prognostic-value-of-cetuximab-related-skin-toxicity-in-metastatic-colorectal-cancer-a-single-institution-analysis
#17
Ana Cvetanovic, Svetislav Vrbic, Sladjana Filipovic, Ivica Pejcic, Dusan Milenkovic, Nikola Zivkovic, Milos Kostic, Ivan Petkovic
PURPOSE: To evaluate the clinical benefits of cetuximab (CTX) and the prognostic value of CTX-related skin toxicity in metastatic colorectal cancer (mCRC) patients. METHODS: Sixty patients were tested for KRAS mutation at the Department of Oncology, Clinical Centre Nis. We assessed 34 wild-type KRAS mCRC patients treated with CTX. All of them were refractory to prior fluoropyrimidine, oxaliplatin and irinotecan-based regimens. The maximum grade skin toxicity according to treatment cycle was analyzed...
January 2014: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://read.qxmd.com/read/24859798/early-skin-toxicity-predicts-better-outcomes-and-early-tumor-shrinkage-predicts-better-response-after-cetuximab-treatment-in-advanced-colorectal-cancer
#18
T Kogawa, A Doi, M Shimokawa, T M Fouad, T Osuga, F Tamura, T Mizushima, T Kimura, S Abe, H Ihara, T Kukitsu, T Sumiyoshi, N Yoshizaki, M Hirayama, T Sasaki, Y Kawarada, S Kitashiro, S Okushiba, H Kondo, Y Tsuji
Cetuximab-containing treatments for metastatic colorectal cancer have been shown to have higher overall response rates and longer progression-free and overall survival than other systemic therapies. Cetuximab-related manifestations, including severe skin toxicity and early tumor shrinkage, have been shown to be predictors of response to cetuximab. We hypothesized that early skin toxicity is a predictor of response and better outcomes in patients with advanced colorectal carcinoma. We retrospectively evaluated 62 patients with colorectal adenocarcinoma who had unresectable tumors and were treated with cetuximab in our institution...
March 2015: Targeted Oncology
https://read.qxmd.com/read/26469836/anti-epidermal-growth-factor-receptor-skin-toxicity-a-matter-of-topical-hydration
#19
Daris Ferrari, Carla Codecà, Barbara Bocci, Francesca Crepaldi, Martina Violati, Giulia Viale, Carmela Careri, Sarah Caldiera, Veronica Bordin, Andrea Luciani, Sabrina Zonato, Gabriela Cassinelli, Paolo Foa
Skin toxicity is a frequent complication of anti-epidermal growth factor receptor therapy, which can be an obstacle in maintaining the dose intensity and may negatively impact on the clinical outcome of cancer patients. Skin lesions depend on the disruption of the keratinocyte development pathways and no treatment is clearly effective in resolving the cutaneous alterations frequently found during anti-epidermal growth factor receptor therapy. Among systemic treatments, oral tetracycline proved to be useful in preventing skin manifestations...
February 2016: Anti-cancer Drugs
https://read.qxmd.com/read/26811634/biomarkers-of-skin-toxicity-induced-by-anti-epidermal-growth-factor-receptor-antibody-treatment-in-colorectal-cancer
#20
REVIEW
Akiko Kubo, Hironobu Hashimoto, Naoki Takahashi, Yasuhide Yamada
Skin toxicity is a common symptom of anti-epidermal growth factor receptor (EGFR) antibody treatment and is also a predictive marker of its efficacy in colorectal cancer patients. However, severe skin disorders induced by such antibodies negatively impact on the quality of life of patients and decreases drug compliance during treatment. If we can predict the high-risk group susceptible to severe skin toxicity before treatment, we can undertake the early management of any arising skin disorders and formulate a more accurate prognosis for anti-EGFR antibody treatment...
January 14, 2016: World Journal of Gastroenterology: WJG
label_collection
label_collection
1405
1
2
2017-02-22 21:36:06
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"